PDSB Projected Dividend Yield
PDS Biotechnology Corp ( NASDAQ : PDSB )PDS Biotechnology Corporation is a clinical-stage immunotherapy company. Co. is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. 20 YEAR PERFORMANCE RESULTS |
PDSB Dividend History Detail PDSB Dividend News PDSB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |